Background: Impaired glymphatic function is linked to cerebral atrophy and contributes to clinical disability in patients with relapsing-remitting multiple sclerosis (RRMS). Deep gray matter volume (DGMV) loss is associated with disability; however, its mediating effect in MS-related disability and glymphatic function changes remains underexplored. Methods: One hundred and thirty-one RRMS patients and 50 healthy controls (HC) underwent MRI scans. The DTI-ALPS index was used to evaluate glymphatic function. Z-scores of cortical and deep gray matter volumes (CGMV and DGMV) and WM-FA in RRMS patients were determined based on the mean and standard deviation of HC. RRMS patients were divided into two subgroups: the “MS-DGM-preserved” subgroup (z-scores of both CGMV, DGMV, and WM-FA > -2) and the “MS-DGM-atrophied” subgroup (z-scores of DGMV < -2) according to combinations of z-scores compared to HC. The mediating effect of DGMV in the relationship between the DTI-ALPS index and the clinical disability was further explored. Patients were followed up and had longitudinal outcomes. Results: Among all participants, 79 cases (60.3%) were classified as the MS-DGM-preserved subgroup, and 52 cases (39.7%) as the MS-DGM-atrophied subgroup. The MS-DGM-atrophied subgroup exhibited lower DTI-ALPS index (d=1.42, p-FDR< 0.001), higher T2-hyperintense white matter lesion volume (d=0.98, p-FDR< 0.001) and EDSS scores (d=0.49, p-FDR< 0.001), and longer disease duration (d=0.33, p-FDR=0.005) compared to the MS-DGM-preserved subgroup. Additionally, in the MS-DGM-atrophied subgroup, the DTI-ALPS index was significantly positively correlated with DGMV (r=0.59, p-FDR<0.001), and negatively correlated with EDSS scores and disease duration (r=-0.59, r=-0.56, p-FDR<0.001). Mediation analysis revealed that DGMV partially mediated the relationship between the DTI-ALPS index and clinical disability (EDSS and disease duration). In the longitudinal cohort, 18 MS patients were followed for a median time of 14 months (12.75, 14.00 months; range: 8–18 months). Compared to baseline, the DTI-ALPS index significantly decreased during follow-up (d=0.92, p-FDR=0.009). Conclusion: The RRMS subgroups based on the gradient classification of DGMV using structural MRI effectively distinguishes differences in glymphatic function and clinical disability. When DGM atrophy reaches a certain threshold, it partially mediates the relationship between glymphatic function and clinical disability.
The clinico-radiological paradox in multiple sclerosis (MS) describes the disconnect between white matter lesion load and clinical disability. This study investigated the role of deep gray matter (DGM) iron deposition in this paradox, specifically regarding cognitive impairment. We classified 134 MS patients into subgroups based on T2-lesion volume (LV) and disability (EDSS): LL/LD, HL/LD, LL/HD, HL/HD, comparing them to 46 healthy controls (HCs). Using quantitative susceptibility mapping (QSM) and volumetric analysis, we assessed iron content and atrophy in DGM nuclei, alongside cognitive testing (MoCA, SDMT). Subgroups with high lesion burden (HL/LD, HL/HD) showed significantly increased iron and atrophy in the globus pallidus, putamen, and caudate versus HCs. A critical group-by-volume interaction on susceptibility was found in the putamen for HL/LD (β=-0.55) and HL/HD (β=-0.35) subgroups. Mediation analysis revealed that putamen volume mediates the effect of iron on cognition, with significant indirect effects on SDMT (β=-0.18) and MoCA (β=-0.14) across all patients. In the HL/HD subgroup, this pathway accounted for 45.8 % of iron's total effect on processing speed (SDMT). Our findings demonstrate heterogeneous DGM iron deposition and identify putaminal iron-induced atrophy as a key mechanistic pathway for cognitive deficits, offering a novel explanation for the paradox and a potential biomarker for cognitive risk stratification.
Objective: Both aquaporin-4 antibody (AQP4) associated optic neuromyelitis spectrum disease (NMOSD) and Myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) involve autoimmune-mediated neuronal damage. Brain damage can have direct or indirect effects on the neurotransmitter system, leading to disruptions and functional abnormalities in neural transmission. By examing a sizable and thoroughly characterized cohort of AQP4+ NMOSD and MOGAD patients, we aimed to compare the spatial distribution of brain lesions in the two diseases and to understand the theoretical bases for location preferences. Next, we explored and compared the association between the characteristics of lesion frequency map and the distribution of neurotransmitters in the whole brain to identify novel therapeutic targets based on neurotransmitter modulation. Methods: We gathered clinical details and MRI data to construct a lesion frequency map in AQP4+ NMOSD and MOGAD patients. Probabilistic lesion distribution maps were created after lesions automatic segmentation and spatial normalization. Lobe-wise and voxel-wise quantitative comparisons of two distributions were performed. JuSpace toolbox was performed to explore whether the lesion frequency map correlated with an abnormal distribution of specific neurotransmitters. Results: The findings showed that both AQP4+ NMOSD and MOGAD patients had supratentorial and infratentorial brain lesions, with the highest probability in the deep sublobular white matter (WM) region in both groups; The MOGAD patients' brain lesions were larger, more concentrated, and more likely to be in the deep sublobular WM, hippocampus, cerebellum, putamen, pons, medulla oblongata, cerebellum and gray matter (GM), as well as WM in the frontal, temporal, and occipital lobes. Eight neurotransmitter levels showed a substantial positive correlation with the lesion probability distribution in AQP4+ NMOSD. On the other hand, only dability distribution of MOGAD lesions and both mGluR5 and 5HT2a. Conversely, only noradrenergic (NAT) and dopaminergic (D2, DAT, FDOPA) neurotransmitters were substantially linked with the lesion probability distribution in MOGAD. Furthermore, mGluR5 and 5HT2a showed a somewhat negative correlation with the probability distribution of MOGAD lesions. The pattern of distribution of brain lesions showed also a significant spatial correspondence with a higher distribution of 5HT1a receptor in MOGAD patients comparing to AQP4+ NMOSD. Conclusion: The lesion spatial distribution results improved our understanding of imaging characteristics in the MOGAD and AQP4+ NMOSD patients. We also revealed that the distribution pattern of brain lesions showed a spatial correspondence with specific neurotransmitter, opening up a novel way to assess lesion location predilection or lesion origin.